Applied Genetics

Applied Genetics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Applied Genetics Laboratories is a well-established, privately-held CRO founded in 2016, with deep roots in cytogenetics dating back over 30 years through its team's experience. The company generates revenue by providing essential, regulatory-compliant cytogenetic services and products to support clients in drug development, vaccine production, and basic research, particularly in areas requiring rigorous genetic validation. Headquartered in Cambridge, USA, AGL leverages a highly experienced scientific team to maintain a niche position as a trusted partner for complex genetic analysis in non-clinical studies.

Rare DiseaseInfectious DiseaseNeuromuscular Diseases

Technology Platform

Suite of classical and molecular cytogenetic analysis techniques (karyotyping, Fluorescence In Situ Hybridization) offered as a GLP-compliant service for cell line characterization, species verification, and genetic monitoring.

Opportunities

Growth in cell/gene therapy and biologics development increases demand for mandatory cell line characterization.
The ongoing need for research reproducibility and cell line authentication provides a steady service stream.
Expansion of service offerings into adjacent areas like digital cytogenetics or basic NGS could capture more value from existing clients.

Risk Factors

Heavy reliance on a niche technical area vulnerable to displacement by newer genomic technologies like NGS.
Business concentration risk tied to biopharma R&D spending cycles.
Dependence on a small group of key technical experts poses succession and scalability challenges.

Competitive Landscape

Competes with cytogenetics service units within large, full-service CROs (e.g., LabCorp, Charles River) and specialized academic core facilities. Differentiation is based on deep expertise, multi-species capability, and a strong focus on GLP compliance for regulatory submissions, rather than price or scale.